Benzinga · Oct 30, 2026
This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday
Analysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR’s target increased to $1,700.
PH
NASDAQ · PHVS
Pharvaris N.V.
Healthcare · Biotechnology
$34.78
Down-$0.45 (-1.29%)
Updated Nov 4, 2026, 10:50 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.56B
- P/E ratio
- -6.64
- Dividend yield
- 0.00%
- 52-week range
- $24.95 – $43.25
- Volume
- 577.62K
- Avg. volume
- 336.54K
Price performance · PHVS
PHVS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
PHVS closed at $34.78 after 21 trading sessions, up 11.76% for the selected period.
- Last close
- $34.78
- Period change
- +11.76%
- Period low
- $27.74
- Period high
- $34.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $33.90 | $35.30 | $33.90 | $34.78 | 577.62K |
| Nov 2, 2026 | $33.68 | $34.21 | $32.90 | $33.53 | 633.06K |
| Oct 30, 2026 | $33.48 | $33.935 | $33.05 | $33.53 | 1.48M |
| Oct 29, 2026 | $32.84 | $33.62 | $32.7001 | $33.58 | 877.87K |
| Oct 28, 2026 | $31.79 | $32.86 | $31.74 | $32.82 | 381.07K |
| Oct 27, 2026 | $31.62 | $32.34 | $31.59 | $31.95 | 230.12K |
| Oct 26, 2026 | $31.38 | $32.08 | $31.30 | $31.54 | 347.68K |
| Oct 23, 2026 | $31.57 | $32.12 | $30.25 | $31.41 | 621.71K |
| Oct 22, 2026 | $30.76 | $31.02 | $29.84 | $30.68 | 347.24K |
| Oct 21, 2026 | $31.22 | $31.50 | $30.55 | $30.66 | 393.58K |
| Oct 20, 2026 | $29.83 | $31.60 | $29.83 | $30.90 | 1.03M |
| Oct 19, 2026 | $27.80 | $29.95 | $27.80 | $29.77 | 917.08K |
| Oct 16, 2026 | $29.50 | $29.54 | $27.68 | $27.74 | 1.31M |
| Oct 15, 2026 | $30.20 | $30.85 | $29.23 | $29.64 | 820.43K |
| Oct 14, 2026 | $30.00 | $30.52 | $29.80 | $30.02 | 400.43K |
| Oct 13, 2026 | $30.68 | $31.205 | $29.99 | $30.02 | 443.98K |
| Oct 12, 2026 | $31.09 | $31.93 | $30.64 | $30.89 | 646.02K |
| Oct 9, 2026 | $31.14 | $31.96 | $31.09 | $31.10 | 754.99K |
| Oct 8, 2026 | $31.57 | $31.57 | $30.30 | $31.12 | 628.23K |
| Oct 7, 2026 | $30.97 | $32.32 | $30.575 | $31.68 | 341.84K |
| Oct 6, 2026 | $30.50 | $31.27 | $30.15 | $31.12 | 778.39K |
Latest PHVS news
The latest Smart Investors Daily articles mentioning PHVS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PHVS research
Overview
Company profile and research snapshot.
Company profile
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $45.60
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 23, 2026 | B of A Securities | Buy | — |
| Sep 10, 2026 | Guggenheim | Buy | — |
| Sep 9, 2026 | Morgan Stanley | Overweight | — |
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Sep 9, 2026 | Wells Fargo | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 29, 2026
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14ZUG, Switzerland, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abst
Benzinga · Oct 29, 2026
This Hilton Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Analysts upgraded VF Corp, Hilton, Ares Capital, eBay and Wintrust Financial, raising targets for VF, Hilton, eBay and Wintrust.
Benzinga · Oct 28, 2026
This Pentair Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Wednesday
Analysts upgraded Pentair to Neutral with a $65 target and Sun Life Financial to Outperform, raising its target to C$122.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
